Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Head Blames Own Structural Problems For Foreign Drug Delays

This article was originally published in PharmAsia News

Executive Summary

Takeda's president says structural differences among pharmaceutical companies from different countries, including Japan, are responsible for approval delays faced by many drug makers in the United States. Yasuchika Hasegawa said his own company is analyzing its responsibility in the delays, and plans discussions with U.S. FDA about approval timelines and details of clinical trials as part of an effort to correct Takeda's structural deficiencies. Astellas Pharma and Daiichi Sankyo are other major Japanese drug makers that have complained about delays hampering their plans for expansion abroad. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071422

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel